LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

Patients with advanced hepatocellular carcinoma (aHCC) not amenable to surgical resection or locoregional therapy may be treated with multitargeted kinase inhibitors or immuno-oncology–based combination therapy. Sorafenib is approved as first-line (1L) therapy but provides only a modest survival benefit. Despite approved 1L therapies for aHCC, there remains an unmet need to prolong survival while improving treatment tolerability. The phase 3...